Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The missed expectations on Mounjaro and Zepbound sales compelled David Risinger of Leerink Partners to lower his firms 12-month price target on Lilly shares but only by 2%, from $990 to $970, though he maintained his firms Outperform rating on the stock
L-L- 2
If you experience severe nausea, vomiting, or side effects, do not attempt to correct these by altering your injection timing
Perspectiva clnica: A pesar de estos efectos secundarios potenciales, la tirzepatida representa un avance significativo en el tratamiento de diabetes tipo 2 y obesidad
US$ 24.74
US$ 26.13
US$ 26.62
US$ 25.47
US$ 25.58
US$ 25.90
